8-K: BioLife Solutions Reports Strong Q2 2026 Results Amid Repligen Acquisition

BioLife Solutions announced a 21% year-over-year revenue increase for Q2 2026, alongside a significant acquisition agreement with Repligen expected to close in Q4 2026.

Summary

• BioLife Solutions reported second quarter 2026 total revenue of $28.5 million, a 21% increase compared to $23.4 million in Q2 2025.
• The company achieved a GAAP gross margin of 64% and a non-GAAP adjusted gross margin of 65% for Q2 2026.
• GAAP net income for Q2 2026 was $45.1 million, which included a $42.4 million non-cash income tax benefit.
• Non-GAAP adjusted EBITDA for Q2 2026 was $7.4 million, representing 26% of revenue.
• A definitive agreement has been signed for Repligen to acquire BioLife for approximately $1.5 billion, with the transaction expected to close in the fourth quarter of 2026.
• BioLife's biopreservation media holds over a 70% market share in U.S. commercial clinical trials, including nearly 80% of Phase III trials.
• The company's products are embedded in 18 unique commercial CGTs as of June 30, 2026, with expectations for 8 additional product approvals or expansions within 12 months.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, driven by strong revenue growth, improved profitability, and the significant acquisition by Repligen, overshadowing minor decreases in gross margins.

Positives

• Total revenue increased by 21% to $28.5 million in Q2 2026 compared to Q2 2025.
• Six-month revenue increased by 23% to $56.0 million compared to the same period in 2025.
• GAAP net income from continuing operations was $45.1 million in Q2 2026, a significant improvement from a net loss of $15.3 million in Q2 2025.
• Adjusted EBITDA increased to $7.4 million (26% of revenue) in Q2 2026 from $5.6 million (24% of revenue) in Q2 2025.
• The company has a strong market position with over 70% market share in biopreservation media for U.S. commercial clinical trials.
• The pending acquisition by Repligen for $1.5 billion provides a substantial valuation for shareholders.
• Cash, cash equivalents, and marketable securities stood at $113.1 million as of June 30, 2026.

Negatives

• GAAP gross margin slightly decreased to 64% in Q2 2026 from 65% in Q2 2025.
• Non-GAAP adjusted gross margin also saw a slight decrease to 65% in Q2 2026 from 66% in Q2 2025.
• The company reported a net loss from discontinued operations of $517 thousand for the three months ended June 30, 2026.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
• The pending acquisition by Repligen is subject to customary closing conditions, including stockholder and regulatory approvals.

Future Outlook

The company anticipates continued growth driven by its biopreservation media franchise and expects the acquisition by Repligen to close in the fourth quarter of 2026. BioLife also expects approvals for 8 additional products, geographic expansions, or new indications within the next 12 months.

Management Comments

• "We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise."
• "This continued performance underscores the important role our technologies play in enabling the advancement of cell and gene therapies."
• "We look forward to building on this foundation through our announced combination with Repligen, which is expected to close in the fourth quarter of 2026."

Industry Context

StockSavvy.ai notes that BioLife Solutions operates in the rapidly growing cell and gene therapy (CGT) market, where its biopreservation tools are critical for maintaining the viability of therapeutic cells. The acquisition by Repligen, a larger player in the bioprocessing space, signals consolidation and strategic alignment within the industry to support the scaling of CGT manufacturing.

Stakeholder Impact

• Shareholders are expected to benefit from the acquisition by Repligen at a total enterprise value of approximately $1.5 billion.
• Employees may experience changes in roles and reporting structures following the acquisition.
• Customers in the CGT market will continue to have access to BioLife's products, potentially with expanded offerings through Repligen.
• Suppliers may see changes in procurement processes and relationships post-acquisition.

Next Steps

• Complete the acquisition by Repligen, expected in the fourth quarter of 2026.
• Continue to embed biopreservation media in clinical trials and pursue new product approvals.
• Integrate operations post-acquisition by Repligen.

Key Dates

Recommendation

The pending acquisition by Repligen at a significant premium suggests a favorable outcome for current shareholders. However, until the deal closes, holding the stock is prudent as the market will likely price it close to the acquisition value, with limited upside beyond that unless the deal faces significant hurdles or a competing offer emerges.

Keywords

cell and gene therapy, biopreservation media, Repligen acquisition, financial results, revenue growth, EBITDA, CGT market, clinical trials